Editas Medicine (EDIT) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
REGENXBIO (RGNX) has outperformed Editas Medicine (EDIT) over the past year, losing 27.7% versus a loss of 30.0%. Over five years, RGNX leads with a -78.9% price change compared with -92.8% for EDIT. REGENXBIO is the larger company by market cap ($501.4 million vs $422.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | RGNX |
|---|---|---|
| Share price | $2.75 | $7.60 |
| Market cap | $422.35M | $501.37M |
| 1-day change | +0.73% | +1.95% |
| YTD return | +34.15% | -47.26% |
| 1-year return | -30.03% | -27.74% |
| 5-year return | -92.77% | -78.87% |
| EPS (TTM) | $-0.68 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $16.19 |
| 52-week low | $1.66 | $5.46 |
| Distance from 52-week high | -36.49% | -53.09% |
| Average volume | 2.48M | 1.53M |
| Shares outstanding | 153.58M | 66.01M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
EDIT vs RGNX FAQ
Which is bigger, Editas Medicine or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $501.37M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or RGNX?
RGNX returned -27.74% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.